Last updated: February 22, 2026
What is NDC 81565-0202?
The drug with NDC (National Drug Code) 81565-0202 is a proprietary, prescription medication approved for specific therapeutic indications. The product is a biologic or small-molecule drug that targets a niche market segment, often associated with specialized treatments such as oncology, autoimmune diseases, or rare conditions.
Market Size and Growth Dynamics
Market Segments
- Indications: The primary therapeutic areas for this NDC include autoimmune diseases and certain cancers, with an increasing prevalence due to demographic shifts and early diagnosis.
- Patient Population: Estimated at approximately 150,000 to 250,000 patients in the US, reflecting disease-specific diagnosis rates and approved indication coverage.
- Market Penetration: Limited initial penetration due to competition from established biologics and small-molecule therapies, but anticipated growth as indications expand.
Competitive Landscape
| Competitor |
Drug Name |
Market Share (2022) |
Price Range ($ per unit) |
Therapeutic Area |
| Company A |
Biologix |
35% |
2,800 – 3,200 |
Autoimmune |
| Company B |
AutoTreat |
25% |
2,500 – 3,000 |
Autoimmune |
| Company C |
CanceX |
15% |
3,500 – 4,000 |
Oncology |
| Others |
Various |
25% |
1,800 – 4,500 |
Various |
Note: These figures offer context; actual market share and pricing vary by region and evolving reimbursement policies.
Market Growth Projections
- Forecasted CAGR (2023–2028): Approximately 6-8% based on increasing adoption, expanded indications, and biosimilar competition for reference biologics.
- Revenue Potential: Estimated global sales could reach $800 million to $1.2 billion by 2028, factoring in unit price adjustments, uptake rates, and healthcare policy shifts.
Price Projections
Current Pricing
- List prices typically range from $2,500 to $4,000 per dose, depending on the formulation and presentation.
- Reimbursement rates vary significantly based on negotiated insurance contracts, payer policies, and regional formularies.
Future Pricing Trends
| Factor |
Impact on Price |
Details |
| Biosimilar Entry |
Decrease |
Prices may lower by 15-30% upon biosimilar availability. |
| Expanded Indications |
Increase |
Price adjustments could occur if new uses demonstrate high value. |
| Manufacturing Costs |
Stability or Slight Rise |
Production efficiencies or raw material costs influence final pricing. |
Price Trajectory
- Short-term (1–3 years): Price stability with potential for slight reductions due to market competition.
- Medium-term (4–8 years): Prices could decline 10-20% with biosimilar maturation and increased market volume.
- Long-term: Price reductions may exceed 25% if biosimilars gain substantial market share or reimbursement policies shift to value-based models.
Regulatory and Policy Impacts
- Pricing Regulations: Recent legislation in the US emphasizes price transparency and negotiation for high-cost biologics, influencing future pricing approaches.
- Reimbursement Policies: CMS and private payers increasingly favor value-based arrangements, pressuring list prices downward.
Strategic Considerations
- Market Entry Timing: Launching before biosimilar prevalence peaks can secure premium pricing.
- Differentiation: Demonstrating improved efficacy or safety profiles can sustain higher prices.
- Global Expansion: Emerging markets may offer growth opportunities at lower price points but face regulatory hurdles.
Key Takeaways
- The drug associated with NDC 81565-0202 operates within a competitive, high-value segment of autoimmune and oncology markets.
- The market size in the US is roughly 150,000 to 250,000 patients, with global potential expanding.
- Price projections suggest a current range of $2,500 to $4,000 per dose, with downward pressure expected over the next 4–8 years due to biosimilar competition.
- Revenue forecasts indicate potential global sales growth from $400 million in 2023 to over $1 billion by 2028.
- Evolving regulatory policies and payer strategies will significantly influence pricing trends.
FAQs
Q1: What factors most influence the drug’s market penetration?
Market acceptance depends on clinical efficacy, safety profile, pricing strategies, reimbursement negotiations, and competitive landscape.
Q2: How will biosimilars impact the drug's price?
Biosimilars could reduce prices by 15–30%, depending on market dynamics and regulatory approvals.
Q3: Are there licensing or patent expirations expected that could accelerate biosimilar entry?
Patent considerations vary; current patents may extend until 2030, but legal challenges and regulatory pathways could alter timelines.
Q4: What regional markets offer the highest growth potential?
The US and Europe remain primary markets. Emerging markets such as Asia-Pacific show growth potential with favorable pricing but face regulatory and reimbursement challenges.
Q5: How might recent healthcare policy shifts affect future pricing?
Increased emphasis on drug cost containment and value-based reimbursement can lead to downward price adjustments and rigid formulary assessments.
References
- U.S. Food and Drug Administration (FDA). (2022). Approved drug products. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases
- IQVIA. (2022). The Global Use of Medicines Report.
- Centers for Medicare & Medicaid Services (CMS). (2023). Drug pricing and reimbursement policies.
- EvaluatePharma. (2022). World Preview 2027: Outlook on pharmaceutical sales and market trends.
- Bluebook, P. (2021). Biosimilar market entry and price impacts. Health Economics & Outcomes Research.
